PA
CMPX icon

Profund Advisors’s Compass Therapeutics CMPX Stock Holding History

Profund Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
95,209
+7,528
+9% +$22.2K 0.01% 1061
2026
Q1 		$464K Buy
87,681
+30,435
+53% +$176K 0.02% 577
2025
Q4 		$307K Buy
57,246
+40,778
+248% +$188K 0.01% 851
2025
Q3 		$57.6K Buy
+16,468
New +$52K ﹤0.01% 1045

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Profund Advisors's CMPX Position: Q2 2026 in Review

Profund Advisors increased its Compass Therapeutics (CMPX) stake by 8.6% in Q2 2026, buying an estimated $22.2K and bringing the position to 95,209 shares worth $209K. The position accounts for 0.01% of the portfolio, ranked #1061.

Profund Advisors first reported a position in CMPX in Q3 2025 and has held it in 4 quarters since. The position peaked at $464K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Profund Advisors held 95,209 shares of Compass Therapeutics worth $209K as of Q2 2026.
  • Profund Advisors bought 7,528 Compass Therapeutics shares in Q2 2026, an estimated $22.2K.
  • Compass Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #1061 holding.
  • Profund Advisors first reported a position in Compass Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Profund Advisors's Compass Therapeutics position peaked at $464K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.